Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Oragenics Inc (NY: OGEN ) 1.060 +0.010 (+0.95%) Streaming Delayed Price Updated: 2:39 PM EDT, Jul 29, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Oragenics Inc < Previous 1 2 Next > Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer June 23, 2022 From Oragenics, Inc. Via Business Wire Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports June 14, 2022 From Oragenics, Inc Via Business Wire Oragenics Issues Letter to Shareholders May 17, 2022 From Oragenics, Inc. Via Business Wire Oragenics to Participate at the World Vaccine Congress Washington 2022 April 18, 2022 From Oragenics, Inc. Via Business Wire Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses April 06, 2022 From Oragenics, Inc. Via Business Wire Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation March 25, 2022 From Oragenics, Inc. Via Business Wire Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1 March 22, 2022 From Oragenics, Inc. Via Business Wire Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum January 26, 2022 From Oragenics, Inc. Via Business Wire Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant December 20, 2021 From Oragenics, Inc. Via Business Wire Oragenics to Participate in Virtual Fireside Chat Hosted by Alliance Global Partners December 09, 2021 From Oragenics, Inc. Via Business Wire Oragenics Co-Authors a Publication Describing the Dual Mechanism of Action of Lantibiotics December 08, 2021 From Oragenics, Inc. Via Business Wire Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate December 01, 2021 From Oragenics, Inc. Via Business Wire Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum November 23, 2021 From Oragenics, Inc. Via Business Wire Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics. October 04, 2021 From Oragenics, Inc. Via Business Wire Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate September 15, 2021 From Oragenics, Inc. Via Business Wire Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants August 30, 2021 From Oragenics, Inc. Via Business Wire Oragenics Announces Postponement of Annual Meeting of Shareholders August 24, 2021 From Oragenics, Inc. Via Business Wire Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines July 27, 2021 From Oragenics, Inc. Via Business Wire Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum July 01, 2021 From Oragenics, Inc. Via Business Wire Oragenics Issues Letter to Shareholders May 18, 2021 From Oragenics, Inc. Via Business Wire Oragenics Announce Changes in Management and Board of Directors May 03, 2021 From Oragenics, Inc. Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.